This article has been updated to include share prices and details.

NEW YORK, Oct. 29 (GenomeWeb News) - Shares in Lynx Therapeutics were down nearly 9 percent at $2.65 in mid-afternoon trade on the Nasdaq exchange after sliding to $2.25 earlier in the day on news that its financial position is more precarious than originally reported.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.